Acalabrutinib with Best Supportive Care in Subjects Hospitalized with COVID-19

A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care versus Best Supportive Care in Subjects Hospitalized with COVID-19

Clinical Trial Protocol ID:

IND Number 149513

Clinical Trial Investigator Name:

Juan D. Pulido, MD

Clinical Trial Protocol Description:

A Phase II study evaluates the safety and efficacy of acalabrutinib in subjects with COVID-19 when administered with Best Supportive Care

Clinical Trial Eligibility Criteria:

In order to participate, you must meet the following criteria:

• Adults 18 to 85 years of age, and capable of providing informed consent
• Confirmation of Sars-CoV-2 infection
• COVID-19 pneumonia (documented radiographically) requiring hospitalization and oxygen saturation <94% on room air or requires supplemental oxygen.
• Able to swallow pills.
• Women of childbearing potential must have negative pregnancy test and willing to use adequate contraception for the duration of the study.

*This is a partial list of eligibility requirements.